Minaris Regenerative Medicine and VectorBuilder Collaborate to Accelerate Therapeutic Breakthroughs
VectorBuilder, a global leader in gene delivery technologies, is thrilled to announce its partnership with Minaris Regenerative Medicine (Minaris), a leading contract development and manufacturing organization (CDMO) focusing on cell and gene therapies (CGT). This strategic collaboration aims to leverage VectorBuilder’s integrative know-how on GMP vector manufacturing and Minaris’s extensive CGT manufacturing track records to further advance comprehensive solutions for customers in need of cutting-edge CGT development.
In this collaboration, Minaris and VectorBuilder will join forces to co-develop a suite of CDMO services tailored to meet the evolving needs of the biotechnology and pharmaceutical industries. Incorporating their expertises, the two companies aim to streamline and strengthen the cell therapy drug production by ex-vivo genetic modification, such as Chimeric Antigen Receptor T-cell (CAR-T) therapy.
"This partnership signifies a pivotal moment for Minaris as we continue our steadfast commitment to delivering state-of-the-art biotechnology products and services," commented Dr. Takuya Muramoto, COO at Minaris. "Through this collaboration with VectorBuilder, we are poised to expand our services and better cater to the needs of the scientific community."
"We are thrilled to join forces with Minaris to extend our outreach and amplify the value we deliver to our clients," remarked Dr. Bruce Lahn, Chief Scientist at VectorBuilder. "Together, we aspire to offer comprehensive solutions that cater to the evolving demands of the biotechnology sector."
Dr. Miho Matakatsu, Managing Director of VectorBuilder Japan, expressed, "Our collaboration with Minaris aligns seamlessly with our mission to empower innovation and drive positive advancements in the bio-medicine landscape. Together, we are poised to make meaningful contributions to the CGT industry, accelerating the development of the CGT industry and expanding our services to better serve our clients."
The collaboration between Minaris and VectorBuilder underscores a shared commitment in advancing the forefront of CGT manufacturing. Both companies are reaffirming their dedications to enabling the next generation of life-saving technologies.
For more information about Minaris and VectorBuilder, please visit www.rm.minaris.com and www.vectorbuilder.com respectively.
About Minaris
Minaris Regenerative Medicine is a leading global contract development and manufacturing organization (CDMO) dedicated to the production of cell and gene therapy products. For more than 20 years, we have been offering clinical and commercial manufacturing services, development solutions, and technologies while providing outstanding quality and reliability.
About VectorBuilder
VectorBuilder is a full-service CDMO with extensive experience in cGMP vector manufacturing. Operating several state-of-the-art facilities, VectorBuilder have supported many customers along their entire drug-discovery pipelines with GMP manufacturing of plasmid DNA, IVT mRNA, and viral vectors such as lentivirus, AAV, adenovirus, MMLV, and other viruses. Besides GMP manufacturing, our CDMO services include process development, analytical development, cell banking, fill/finish, and regulatory support. VectorBuilder have provided IND-enabling vectors to a worldwide client base in the US, Europe, Japan, China and South Korea.